6 Mercaptopurine

DRUG5 trials

Sponsors

Teva GTC, Massachusetts General Hospital, Tel-Aviv Sourasky Medical Center, Indiana University

Conditions

Acute Lymphoblastic LeukemiaCrohn DiseaseCrohn's DiseaseCrohns DiseaseInflammatory Bowel DiseaseUlcerative Colitis

Phase 1

Pilot Comparative Bioavailability Study of 6Mercaptopurine (Delayed Release vs. Purinethol) in Crohns Disease Patients

CompletedNCT00774982

Teva GTCCrohns Disease

Start: 2008-12-31End: 2009-02-28Updated: 2009-07-17

Multicenter Clinical Efficacy and Safety Study of Delayed Release 6MP in Crohn's Disease

TerminatedNCT01094613

Teva GTCCrohn's Disease

Start: 2010-11-30End: 2012-12-31Updated: 2013-03-07

Phase 2

Treatment of Older Adults With Acute Lymphoblastic Leukemia

CompletedNCT00973752

Massachusetts General HospitalAcute Lymphoblastic Leukemia

Start: 2009-08-31End: 2016-04-30Updated: 2017-03-30

Phase 3

Adalimumab for the Management of Post-operative Crohn's Disease (CD)

Tel-Aviv Sourasky Medical CenterCrohn Disease

Start: 2012-07-31End: 2016-07-31Target: 100Updated: 2012-06-27

Unknown Phase

Evaluate if Response to Infliximab or Adalimumab May be Regained With an Immunomodulator

TerminatedNCT02413047

Indiana UniversityCrohn's Disease, Inflammatory Bowel Disease, Ulcerative Colitis

Start: 2015-05-31End: 2018-02-28Updated: 2019-11-04

Related Papers

Early Initiation of Adalimumab Significantly Diminishes Postoperative Crohn’s Disease Endoscopic Recurrence and Is Superior to 6-Mercaptopurine Therapy: An Open-Label, Randomized Controlled Study

Journal of Clinical Medicine2023-12-105 citations

Phase 2 study of intensified chemotherapy and allogeneic hematopoietic stem cell transplantation for older patients with acute lymphoblastic leukemia.

2016-05-1219 citations